CPI-1189

• UNSPSC Description:

  CPI-1189 is an orally active TNF-α release inhibitor. CPI-1189 inhibits phosphorylation of p38. CPI-1189 can inhibit apoptosis. CPI-1189 can be used in the study of HIV and neurological diseases[1][2][3][4][5].

• Target Antigen:

  Apoptosis; TNF Receptor

• Type:

  Reference compound

• Related Pathways:

  Apoptosis

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Infection; Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/cpi-1189.html

• Purity:

  99.82

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O=C(NC(C)(C)C)C1=CC=C(NC(C)=O)C=C1

• Molecular Weight:

  234.299

• References & Citations:

  [1]Müller T. CPI-1189. Centaur. Curr Opin Investig Drugs. 2002 Dec;3(12):1763-7. |[2]Clifford DB, et al. A randomized clinical trial of CPI-1189 for HIV-associated cognitive-motor impairment. Neurology. 2002 Nov 26;59(10):1568-73.|[3]Li YJ, et al. CPI-1189 protects neuronal cells from oxygen glucose deprivation/re-oxygenation-induced oxidative injury and cell death. Aging (Albany NY). 2021 Feb 17;13(5):6712-6723.|[4]Hensley K, et al. CPI-1189 inhibits interleukin 1beta-induced p38-mitogen-activated protein kinase phosphorylation: an explanation for its neuroprotective properties? Neurosci Lett. 2000 Mar 10;281(2-3):179-82.|[5]Bjugstad KB, et al. Preventive actions of a synthetic antioxidant in a novel animal model of AIDS dementia. Brain Res. 1998 Jun 8;795(1-2):349-57.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C, 3 years (Powder)

• Clinical Information:

  Phase 2

• CAS Number:

  183619-38-7